Effect of GM-CSF and IL-2 co-expression on the anti-tumor immune response

Anticancer Research

Volumn 20, Issue 4, 2000, Pages 2681-2686

  Lee, Sang Goo ^a,b   Heo, Dae Seog ^c   Yoon, Seong Jun ^a   Jee, Youn Suk ^a   Kang, Jung Ok ^a   Kim, Kyungjin ^b   Kim, Chun Dong ^c   Sung, Myung Whun ^c   Kim, Noe Kyeong ^c  

^a Institute of Molecular Biology and Genetics   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Gene therapy; GM CSF; IL 2; Retrovirus

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENICITY; CELL LINE; GROWTH RATE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MONOCYTE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY;

ANIMALS; BLOTTING, NORTHERN; GENE THERAPY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-2; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0033866726     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Armstrong CA, Botella R, Galloway TH, Murray N, Kramp JM, Song IS and Ansel JC: Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells. Cancer Res 56: 2191-2198, 1996.
2. Anderson FW: Gene therapy of cancer. Hum Gene Ther 5: 1-2, 1994.
3. Chen SH, Chen XHL, Wang Y, Kosai KI, Finegold MJ, Rich SS and Woo SLC: Combination gene therapy for liver metastasis of colon adenocarcinoma in vivo. Proc Nat Acad Sci Wash 92: 2577-2581, 1995.
4. Chen SH, Chen XHL, Wang Y, Kosai KI, Finegold MJ, Rich SS and Woo SLC: Combination gene therapy for liver metastasis of colon adenocarcinoma in vivo. Proc Natl Acads Sci 92: 2577-2581, 1995.
5. Colombo MP and Forni G: Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 15: 48-51, 1994.
6. Connor J, Bannerji R, Saito S, Heston W, Fair W and Gilboa E: Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med 177: 1127-1134, 1993.
7. Danos O and Mulligan RC: Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Nat Acad Sci Wash 85: 6460-6464, 1988.
8. Dilloo D, Bacon K, Holden W, Zhong W, Burdach S, Zlotnik A and Brenner M: Combined chemokine and cytokine gene transfer enhances anti-tumor immunity. Nature Med 2: 1090-1095, 1996.
9. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levisky H, Brose K, Jackson V, Hamada H, Pardoll D and Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte macrophage colony-stimulating factor stimulates potent, specific, and long lasting anti-tumor immunity. Proc Nat Acad Sci Wash 90: 3539-3543, 1993.
10. Fakhrai H and Mains MD: Expression and characterization of a cDNA for rat kidney biliverdin reductase. J Biol Chem 267: 4023-4029, 1995.
11. Fakhrai H, Shawler DL, Gjerset R, Naviaux RK, Koziol J, Royston I and Sobol RE: Cytokine gene therapy with IL-2 transduced fibroblast: Effect of IL-2 dose on anti-tumor immunity. Hum Gene her 6: 591-601, 1995.
12. Fearon E, Pardoll D, Itaya T, Golumbek P, Levisky HI, Simons JW, Karasuyama H, Vogelstein B and Frost P: Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60: 397-403, 1990.
13. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R and Gilboa E: Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172: 1217-1224, 1990.
14. Goldsmith MA and Greene WC: Interleukin-2 and the interleukin-2 receptor, ed Thomsom A (Harcourt Brace Jovanovich), 2: 57-80, 1995.
15. Golumbek PT, Cazenby AJ, Levisky HI, Jaffee LM, Karasuyama H, Baker M and Pardoll DM: Transduction of established renal cancer by tumor cells engineered to secrete IL-2. Science 254: 713-717, 1991.
16. Hollignsworth SJ, DArling D, Gaken J, irst W, Patel P, Kuiper M, Towner P, Humphreys S, Farzaneh F and Mufti GJ: The effect of combined expression of interleukin 2 and interleukin 4 on the tumorigenicity and treatment of B16F10 melanoma. Brit J Cancer 74: 6-15, 1996.
17. Jang SK, Krausslich HG, Nicklin MJH, Duke GM, Palmenberg AC and Wimmer E: A segment of the 5′ nontranslated region of encephalomyocarditis virus RNA directs internal entry of ribosomes during in vitro translation. J Virol 62: 2636-2643, 1996.
18. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT and Rosenber SA: High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. J Am Med Assoc 526: 3117-3124, 1986.
19. Maas RA, Dullens HFJ and Otter WD: Interleukin-2 in cancer treatment: disappointing or (still) promising? A review. Cancer Immunol Immunother 36: 141-148, 1993.
20. Markowitz D, Hesdorffer C, Ward M, Goff S and Bank A: Retroviral gene transfer using safe and efficient packaging cell lines. Ann NY Acad Sci 612: 407-414, 1990.